Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast

  • Research Article
  • Published:
Tumor Biology

Abstract

Patients with microinvasive carcinoma often have favorable prognosis, but it remains unclear whether this special type of breast cancer represents a distinct morphological entity with its own biological features and clinical behavior distinct from those of ductal carcinoma in situ (DCIS). The study is a retrospective analysis of a large patient cohort from a single institution. One hundred and thirty one microinvasive carcinoma and 451 DCIS cases were collected. ER, PR, HER2, and Ki67 were examined by immunohistochemistry in pathological sections. We assessed the clinicopathologic characteristics, molecular features, and survival status of microinvasive carcinoma and compared to those of DCIS. Microinvasive carcinoma differed from DCIS with respect to tumor size, lymph node status, and initial presentation (P < 0.05). There was a significant difference in nuclear grade among microinvasive carcinoma of different molecular subtype (P < 0.05). The clinicalpathologic features and outcomes of patients with microinvasive carcinoma were similar to those with DCIS. The 5-year OS rate for microinvasive carcinoma and DCIS patients was 99.0 and 99.2 %, respectively. A combination of pathologic, clinical, and molecular factors may ultimately reveal more powerful and robust measures for disease classification than any one modality alone. Microinvasive carcinoma does not significantly predict for worse DFS or OS in comparison with patients with DCIS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  PubMed  Google Scholar 

  2. Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, et al. Breast cancer in a transitional society over 18 years: Trends and present status in Shanghai, China. Breast Cancer Res Treat. 2009;117:409–16.

    Article  PubMed  Google Scholar 

  3. de Mascarel I, MacGrogan G, Mathoulin Pélissier S, Soubeyran I, Picot V, Coindre JM. Breast ductal carcinoma in situ with microinvasion. Cancer. 2002;94:2134–42.

    Article  PubMed  Google Scholar 

  4. Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, et al. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol. 2011;18:1342–8.

    Article  PubMed  Google Scholar 

  5. Vieira CC, Mercado CL, Cangiarella JF, Moy L, Toth HK, Guth AA. Microinvasive ductal carcinoma in situ: Clinical presentation, imaging features, pathologic findings, and outcome. Eur J Radiol. 2010;73:102–7.

    Article  PubMed  Google Scholar 

  6. Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer. 1998;82:2382–90.

    Article  CAS  PubMed  Google Scholar 

  7. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short‐term treatment failures. Cancer. 1982;50:1309–14.

    Article  CAS  PubMed  Google Scholar 

  8. Ellis IO, Tavassoli FA. Microinvasive carcinoma. In: Tavassoli FA, Devilee P, editors. Pathology & genetics: Tumours of the breast and female genital organs. 3rd ed. Lyon: IARC Press; 2003. p. 74–5.

    Google Scholar 

  9. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.

    Article  PubMed  Google Scholar 

  10. Pinder SE, Ellis IO, Schnitt SJ, Tan PH, Rutgers E, Morrow M. Microinvasive carcinoma. In: Lakhani SR, Ellis IO, Schnitt SJ, editors. WHO classification of tumours of the breast. 4th ed. Lyon: IARC Press; 2012. p. 96–7.

    Google Scholar 

  11. Clark S, Warwick J, Carpenter R, Bowen R, Duffy S, Jones J. Molecular subtyping of DCIS: Heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer. 2011;104:120–7.

    Article  CAS  PubMed  Google Scholar 

  12. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102:170–8.

    Article  PubMed  Google Scholar 

  14. Welch HG, Schwartz LM, Woloshin S. Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers. BMJ. 2006;332:727.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Olivotto I, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). C M A J. 2001;165:912–3.

    CAS  Google Scholar 

  16. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer Educ. 2011;2:232.

    Article  Google Scholar 

  17. Daly MB. Tamoxifen in ductal carcinoma in situ. Semin Oncol. 2006;33:647–9.

    Article  PubMed  Google Scholar 

  18. Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2012;106:1160–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, et al. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—Results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat. 2012;132:863–70.

    Article  CAS  Google Scholar 

  20. Horimoto Y, Tokuda E, Arakawa A, Kosaka T, Saito M, Kasumi F. Significance of HER2 protein examination in ductal carcinoma in situ. J Surg Res. 2011;167:e205–10.

    Article  CAS  PubMed  Google Scholar 

  21. Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:1386–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kurbel S. In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer. Tumour Biol. 2013;34:1–7.

    Article  CAS  PubMed  Google Scholar 

  23. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441–52.

    Article  CAS  PubMed  Google Scholar 

  24. Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12:21–9.

    Article  CAS  PubMed  Google Scholar 

  25. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by National Science Foundation of China (81470119; 81172532).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Breast Cancer Pathology and Research Laboratory, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education. Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, West Huanhu Road, Ti Yuan Bei, Hexi District, Tianjin, 300060, China

    Li Wang, Wei Zhang, Shuhua Lyu, Xia Liu, Tongxian Zhang, Shan Liu, Ying Qin, Xiaoqi Tian & Yun Niu

  2. Department of Pathology, Nankai University Affiliated Hospital, 190, Jie-Yuan Road, Hongqiao District, Tianjin, 300121, China

    Shuhua Lyu

Authors
  1. Li Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuhua Lyu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xia Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tongxian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ying Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiaoqi Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yun Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yun Niu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, L., Zhang, W., Lyu, S. et al. Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast. Tumor Biol. 36, 2241–2248 (2015). https://doi.org/10.1007/s13277-014-2652-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2652-z

Keywords

Search

Navigation